Cryo-Cell International, Inc. (CCEL) Fair Value 2026

CCEL · Services-Misc Health & Allied Services, NEC ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.4 /10

32 fundamental signals · 12 models active

Value Trap Risk

SAFE (12/100)

Quick Summary — As of 2026-07-13, Cryo-Cell International, Inc. (CCEL) trades at $3.50, approximately 14% below CirclFi’s Bayesian DCF fair value of $4.06. QOC: 7.4/10. Value Trap Risk: 12/100 (SAFE). 12/13 models active.

Key Facts

Ticker
CCEL
Price
$3.50
Quality Score
7.4/10
Value Trap Risk
12/100
Models Active
12/13
Last Updated
Strength: Earnings Power Value suggests +72.4% upside with 80% confidence
Risk: Limited model coverage (12/13) may reduce confidence

Valuation Matrix

12 Intrinsic Value Models vs. Current Price ($3.50)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
High Conviction
 $4.06 +15.9%
Earnings Power Value
High Conviction
 $6.03 +72.4%
CUCE Ensemble
Medium Conviction
 $5.13 +46.5%
First Chicago
High Conviction
 $3.61 +3.2%

Unlock the Full Matrix

Access 8 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 12 Models →

Cancel anytime · No contracts · Instant access

What Is Cryo-Cell International, Inc. (CCEL) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for Cryo-Cell International, Inc.. Trading at $3.50 against an estimated intrinsic value of $4.92, 10 of 12 active models flag meaningful upside of +40.7% on average. The most optimistic model, Markov DDM, places fair value at $8.23 (+135.2%), while EROIC — the most conservative — estimates $0.87 (-75.2%). This +210.4% gap reflects genuine analytical uncertainty about Cryo-Cell International, Inc.'s intrinsic worth. Among models with highest confidence, Bayesian DCF, EPV lean bullish — adding weight to the bullish side of the thesis.

What Do the Models Say About CCEL?

12 of 13 models are currently active for CCEL. Of these, 11 models suggest upside while 1 model suggests overvaluation. The Bayesian DCF estimates CCEL's intrinsic value at $4.06, implying +15.9% upside from the current price. See which stocks rank higher →

How Does CCEL Rank in Services-Misc Health & Allied Services, NEC?

Among 11 Services-Misc Health & Allied Services, NEC stocks, CCEL ranks #5 by Quality of Company score. CirclFi's QOC score of 7.4/10 evaluates 32 fundamental signals. A score of 7.4 indicates above-average quality.

Cryo-Cell International, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is CCEL a Value Trap?

CirclFi's Value Trap algorithm assigns CCEL a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

12 of 13 models are active for Cryo-Cell International, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Cryo-Cell International, Inc.'s fundamental quality profile registers 7.4/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +210.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CCEL valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CCEL's 12 active models, average confidence is 50%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Cryo-Cell International, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Services-Misc Health & Allied Services, NEC Stocks Should You Also Analyze?

8 related Services-Misc Health & Allied Services, NEC stocks with 13-model coverage

PGNYProgyny, Inc.QOC 8.5SHCSotera Health CompanyQOC 8.1VMDViemed Healthcare, Inc.QOC 7.9DVADaVita Inc.QOC 7.6BRTXBioRestorative Therapies, Inc.QOC 6.6MGRXMangoceuticals, Inc.QOC 5.2NIVFNewGenIvf Group LimitedQOC 2.0FMSFresenius Medical Care AGQOC 2.0

Read investment analysis: PGNY · SHC · VMD · DVA · BRTX

Frequently Asked Questions About Cryo-Cell International, Inc.

What is Cryo-Cell International, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Cryo-Cell International, Inc. (CCEL) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $4.06. The Quality of Company score is 7.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CCEL overvalued or undervalued right now?

At $3.50, 11 of 12 active models suggest CCEL may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Cryo-Cell International, Inc.'s business model in Services-Misc Health & Allied Services, NEC.

What does a Quality of Company score of 7.4 mean for CCEL?

Cryo-Cell International, Inc.'s QOC of 7.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on CCEL?

CirclFi analyzes CCEL with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 12 of 13 are active for this stock. Read the full methodology →

Is CCEL a value trap in 2026?

Cryo-Cell International, Inc.'s Value Trap score is 12/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 12 mathematical frameworks give you clarity on CCEL.

Unlock All 12 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access